Results 61 to 70 of about 34,473 (219)

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

A case report of drug–drug interaction between voriconazole and simnotrelvir/ritonavir

Frontiers in Antibiotics
Co-administration of simnotrelvir/ritonavir with voriconazole should be avoided, as stated in the product insert of simnotrelvir/ritonavir, due to the anticipated decrease in the plasma concentration of voriconazole.
Tingting Chen, Qingquan Zhang
doaj   +1 more source

Emergence of Trichophyton indotineae in Switzerland (2014–2025): Clinical analysis and antifungal susceptibility

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Trichophyton indotineae is an emerging dermatophyte associated with chronic, recalcitrant dermatophytosis and terbinafine resistance due to squalene epoxidase (SQLE) mutations. We analyzed clinical characteristics, antifungal susceptibility profiles, SQLE mutations, and treatment outcomes of cases diagnosed in ...
Annabel H. Lechner, Dennis D. Arnold, Philipp P. Bosshard   +2 more
wiley   +1 more source

Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis.

PLoS ONE, 2020
BackgroundChronic pulmonary aspergillosis (CPA) requires prolonged treatment with itraconazole or voriconazole. However, adverse events (AEs) are common with the use of these agents, with the need to discontinue the offending drug in a significant ...
Ronald Olum, Joseph Baruch Baluku, Andrew Kazibwe, Laura Russell, Felix Bongomin   +4 more
doaj   +1 more source

Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis

Frontiers in Pharmacology
Voriconazole is a broad-spectrum triazole antifungal agent. A number of studies have revealed that the impact of C-reactive protein (CRP) on voriconazole pharmacokinetics was associated with the CYP2C19 phenotype. However, the combined effects of CYP2C19
Jing Ling, Xuping Yang, Lulu Dong, Yan Jiang, Sulan Zou, Nan Hu   +5 more
doaj   +1 more source

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

Internal Medicine Journal, EarlyView.
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid, Jackson L. A. Thomas, Luke B. Hesson, Stephen Hughes, Sophie L. Stocker   +4 more
wiley   +1 more source

A 23 bp cyp51A Promoter Deletion Associated With Voriconazole Resistance in Clinical and Environmental Isolates of Neocosmospora keratoplastica

Frontiers in Microbiology, 2020
In the fungal pathogen Aspergillus fumigatus, resistance to azole antifungals is often linked to mutations in CYP51A, a gene that encodes the azole antifungal drug target lanosterol 14α-demethylase.
Jasper Elvin James, Erwin Lamping, Jacinta Santhanam, Trudy Jane Milne, Mohd Fuat Abd Razak, Latiffah Zakaria, Richard David Cannon   +6 more
doaj   +1 more source

ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand

Internal Medicine Journal, EarlyView.
Abstract Background Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients.
Andrea Henden, Lynette Chee, Julia Clark, Rachel Conyers, Julian Cooney, Richard Doocey, David Gottlieb, Tim Prestidge, Madeleine Powys, Philip Selby, Gaurav Sutrave, Eric Wong, Michelle K. Yong, Nada Hamad   +13 more
wiley   +1 more source

Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations [PDF]

AIMS: Voriconazole is extensively metabolized via cytochrome P450 (CYP) enzymes, predominantly CYP2C19 and CYP3A4. Drugs influencing the activity or expression of CYP enzymes can cause clinically relevant changes in the metabolism and voriconazole ...
Baan, Simone D, Oude Munnink, Thijs H; id_orcid, Touw, Daan J; id_orcid, Lub-de Hooge, Marjolijn N; id_orcid   +3 more
core   +1 more source

Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta, Tong Wang, Susmita, Ditte Marie L. Saunte, Roderick Hay, Vincent Piguet   +5 more
wiley   +1 more source